Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!

References

• Sangro P, de la Torre Aláez M, Sangro B, et al. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. J Physiol Biochem. 2023;79(4):869–879. doi: 10.1007/s13105-023-00954-4
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Alharthi J, Gastaldelli A, Cua IH, et al. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260. doi: 10.1097/MOG.0000000000000823
   PubMed Web of Science ®Google Scholar
• Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128. doi: 10.1111/hepr.13685
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and europe. Hepatology. 2016;64(5):1577–1586. doi: 10.1002/hep.28785
   PubMed Web of Science ®Google Scholar
• Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022 Aug 18;107(9):2691–2700. doi: 10.1210/clinem/dgac321
   PubMed Web of Science ®Google Scholar
• Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651. doi: 10.1038/s41575-022-00635-5
   PubMed Web of Science ®Google Scholar
• Adams LA, Roberts SK, Strasser SI, et al. Nonalcoholic fatty liver disease burden: Australia, 2019-2030. J Gastroenterol Hepatol. 2020;35(9):1628–1635. doi: 10.1111/jgh.15009
   PubMed Web of Science ®Google Scholar
• Yang K, Song M. New insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): Gut-liver-Heart Crosstalk. Nutrients. 2023;15(18):3970. doi: 10.3390/nu15183970
   PubMed Web of Science ®Google Scholar
• Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092. doi: 10.1016/j.molmet.2020.101092
   PubMed Web of Science ®Google Scholar
• Fricker ZP, Pedley A, Massaro JM, et al. Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham heart study. Clin Gastroenterol Hepatol. 2019;17(6):1157–1164.e4. doi: 10.1016/j.cgh.2018.11.037
   PubMed Web of Science ®Google Scholar
• Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42(7):573–582. doi: 10.1007/s00535-007-2060-x
   PubMed Web of Science ®Google Scholar
• VanWagner LB, Wilcox JE, Ning H, et al. Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study. J Am Heart Assoc. 2020;9(4):e014279. doi: 10.1161/JAHA.119.014279
   PubMed Web of Science ®Google Scholar
• Simon TG, Bamira DG, Chung RT, et al. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity (Silver Spring). 2017;25(8):1313–1316. doi: 10.1002/oby.21879
   PubMed Web of Science ®Google Scholar
• Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res. 2021;49(9):3000605211047074.
   Web of Science ®Google Scholar
• Glass LM, Hunt CM, Fuchs M, et al. Comorbidities and nonalcoholic fatty liver disease: the chicken, the egg, or both? Fed Pract. 2019;36(2):64–71.
   PubMedGoogle Scholar
• Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600. doi: 10.1016/j.jhep.2016.05.013
   PubMed Web of Science ®Google Scholar
• Meyersohn NM, Mayrhofer T, Corey KE, et al. Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease. Clin Gastroenterol Hepatol. 2021;19(7):1480–1488.e14. doi: 10.1016/j.cgh.2020.07.030
   PubMed Web of Science ®Google Scholar
• Tamaki N, Higuchi M, Kurosaki M, et al. Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(5):1171–1173.e2. doi: 10.1016/j.cgh.2021.07.021
   PubMed Web of Science ®Google Scholar
• Kongmalai T, Srinonprasert V, Anothaisintawee T, et al. New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol. 2023;14:1182037. doi: 10.3389/fendo.2023.1182037
   PubMedGoogle Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124. doi: 10.1056/NEJMoa2028395
   PubMed Web of Science ®Google Scholar
• Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352–1355. doi: 10.2337/dc19-1892
   PubMed Web of Science ®Google Scholar
• Arvanitakis K, Koufakis T, Kotsa K, et al. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: from molecular mechanisms to potential clinical implications. Pharmacol Res. 2022;181:106261. doi: 10.1016/j.phrs.2022.106261
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685. doi: 10.1056/NEJMoa0907929
   PubMed Web of Science ®Google Scholar
• Koufakis T, Tsimihodimos V, Metallidis S, et al. The effects of sodium-glucose cotransporter 2 inhibitors beyond the cardio-renal-metabolic spectrum: will gliflozins have a different fate than statins? Expert Opin Pharmacother. 2023;24(16):1753–1756. doi: 10.1080/14656566.2023.2250255
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Paik JM, Biswas R, et al. Poor awareness of liver disease among adults with NAFLD in the United States. Hepatol Commun. 2021;5(11):1833–1847. doi: 10.1002/hep4.1765
   PubMed Web of Science ®Google Scholar
• Wessels DH, Rosenberg Z. Awareness of non-alcoholic steatohepatitis and treatment guidelines: what are physicians telling us? World J Hepatol. 2021;13(2):233–241. doi: 10.4254/wjh.v13.i2.233
   PubMed Web of Science ®Google Scholar
• Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(13):2776–2784.e4. doi: 10.1016/j.cgh.2019.04.061
   PubMed Web of Science ®Google Scholar
• Nascimbeni F, Pellegrini E, Lugari S, et al. Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes. Atherosclerosis. 2019;284:66–74. doi: 10.1016/j.atherosclerosis.2019.02.028
   PubMed Web of Science ®Google Scholar
• Shang Y, Hagström H. Statins are underused in women with NAFLD after cardiovascular events compared with matched control subjects. Clin Gastroenterol Hepatol. 2023;21(5):1359–1361.e2.
   PubMed Web of Science ®Google Scholar
• Blais P, Lin M, Kramer JR, et al. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci. 2016;61(6):1714–20. doi: 10.1007/s10620-015-4000-6
   PubMed Web of Science ®Google Scholar
• Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773–791. doi: 10.1007/s12072-023-10543-8
   PubMed Web of Science ®Google Scholar
• Eslam M, Ahmed A, Després JP, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6(9):743–753. doi: 10.1016/S2468-1253(21)00132-1
   PubMed Web of Science ®Google Scholar